Prognostic Role of Systemic Inflammation Indexes in Metastatic Urothelial Carcinoma Treated With Immunotherapy

References

• SungH , FerlayJ , SiegelRLet al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• PowlesT , BellmuntJ , ComperatEet al.Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol.33(3), 244–258 (2022).
   PubMed Web of Science ®Google Scholar
• PierantoniF , MaruzzoM , GardiMet al.Immunotherapy and urothelial carcinoma: an overview and future prospectives. Crit. Rev. Oncol. Hematol.143, 46–55 (2019).
   PubMed Web of Science ®Google Scholar
• BellmuntJ , NecchiA , DeWit Ret al.Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. J. Clin. Oncol.39(Suppl. 15), 4532 (2021).
   Web of Science ®Google Scholar
• BellmuntJ , de WitR , VaughnDJet al.Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med.376(11), 1015–1026 (2017).
   PubMed Web of Science ®Google Scholar
• PowlesT , ParkSH , VoogEet al.Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med.383(13), 1218–1230 (2020).
   PubMed Web of Science ®Google Scholar
• PowlesT , ParkSH , VoogEet al.Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the JAVELIN Bladder 100 trial. J. Clin. Oncol.40(Suppl. 6), 487 (2022).
   Google Scholar
• SonpavdeG , PondGR , FougerayRet al.Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur. Urol.63(4), 717–723 (2013).
   PubMed Web of Science ®Google Scholar
• BellmuntJ , ChoueiriTK , FougerayRet al.Prognostic Factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol.28(11), 1850–1855 (2010).
   PubMed Web of Science ®Google Scholar
• RebuzziSE , BannaGL , MurianniVet al.Prognostic and predictive factors in advanced urothelial carcinoma treated with immune checkpoint inhibitors: a review of the current evidence. Cancers.13(21), 5517 (2021).
   PubMed Web of Science ®Google Scholar
• RaggiD , GiannatempoP , MarandinoLet al.Role of Bone metastases in patients receiving immunotherapy for pre-treated urothelial carcinoma: the multicentre, retrospective Meet-URO-1 Bone Study. Clin. Genitourin. Cancer.20(2), 155–164 (2022).
   PubMed Web of Science ®Google Scholar
• FornariniG , RebuzziSE , BannaGLet al.Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open.6(3), 100118 (2021).
   PubMed Web of Science ®Google Scholar
• KadonoY , KawaguchiS , NoharaTet al.Blood cell count biomarkers predicting efficacy of pembrolizumab as second-line therapy for advanced urothelial carcinoma. Anticancer Res.41(3), 1599–1606 (2021).
   PubMed Web of Science ®Google Scholar
• JanHC , YangWH , OuCH. Combination of the Preoperative systemic immune-inflammation index and monocyte-lymphocyte ratio as a novel prognostic factor in patients with upper-tract urothelial carcinoma. Ann. Surg. Oncol.26(2), 669–684 (2019).
   PubMed Web of Science ®Google Scholar
• YukHD , KuJH. Role of systemic inflammatory response markers in urothelial carcinoma. Front. Oncol.10, 1473 (2020).
   PubMed Web of Science ®Google Scholar
• TsujinoT , KomuraK , IchihashiAet al.The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma. Oncotarget.8(66), 110311–110325 (2017)
   PubMedGoogle Scholar
• UchimotoT , NakamuraK , KomuraKet al.Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma. Urol Oncol.40(7), 344.e11–344.e17 (2022)
   PubMed Web of Science ®Google Scholar
• RebuzziSE , SignoriA , StellatoMet al.The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: the Δ-Meet-URO analysis. Front Oncol.23(12), 955501 (2022).
   Google Scholar
• TuralD , ÖlmezÖF , SümbülATet al.Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. Int J Clin Oncol.26(8), 1506–1513 (2021)
   PubMed Web of Science ®Google Scholar
• PavanA , CalvettiL , DalMaso Aet al.Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. The Oncologist.24(8), 1128–1136 (2019).
   PubMed Web of Science ®Google Scholar
• BannaGL , DiQuattro R , MalatinoLet al.Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. Clin. Transl. Oncol.22(11), 2130–2135 (2022).
   Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Adverse (CTCAE), version 5.0 (2017). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
   Google Scholar
• EisenhauerEA , TherasseP , BogaertsJet al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• SonpavdeG , ManitzJ , GaoCet al.Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors. J. Urol.204(6), 1173–1179 (2020).
   PubMed Web of Science ®Google Scholar
• FornariniG , RebuzziSE , ButiSet al.A novel immunotherapy prognostic score for patients with pretreated advanced urinary tract carcinoma from the subgroup analysis of the SAUL study: the ITACA score. Minerva Urol. Nephrol75(3), 308–318 (2022).
   PubMedGoogle Scholar
• KobayashiK , SuzukiK , HiraideMet al.Association of immune-related adverse events with pembrolizumab efficacy in the treatment of advanced urothelial carcinoma. Oncology98(4), 237–242 (2020).
   PubMed Web of Science ®Google Scholar
• NishimuraK , NishioK , HirosunaKet al.Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. J Immunother Cancer.10(1), e003868 (2022).
   PubMed Web of Science ®Google Scholar